Avaliação de prognostico do carcinoma de tireoide atraves de marcadores imunoistoquimicos / Evaluation of prognostic of the thyroid carcinoma through immunohistochemical markers

AUTOR(ES)
DATA DE PUBLICAÇÃO

2006

RESUMO

Because most differentiated thyroid carcinomas have an excellent prognosis, some authors have been claiming that these patients have been over-treated. Combinations of patient-and tumor-specific factors have been proposed for prognostic stratification, but no clinicpathologic staging was demonstrated to be useful at the present time. In order to investigate the clinical utility of immunohistochemistry markers, we studied 67 thyroid nodules including 50 thyroid carcinomas. There were 34 (50,74%) papillary carcinomas, including 21 (31,3%) cases of the classical histological type, 7 (10,4%) tall cell variants and 6 (9%) of the follicular variant type. Also, there were 16 (23,9%) follicular carcinomas, 4 (6%) medullary and 3 anaplastic carcinomas (4,5%). Ten patients (14,9%) were submitted to surgery because of benign thyroid diseases (3 nodular goiter cases, 4 follicular adenomas and 3 thyroid tissues normal). All patients were submitted to a similar management protocol and followed-up for 66±28 months (median of 63 months) and classified as presenting a good or a bad evolution. We considered as presenting a bad evolution 19 patients that presented evidence of local or distant recurrence and the patients that died during the follow-up. Immunohistochemical expression of NIS, p53 and MUC1 proteins was compared to patient?s evolution. We showed that patient with well differentiated thyroid carcinomas, absence of distant metastases, stage II and staging T2 have a better evolution in relation to the patients with poorly differentiated thyroid carcinomas, presence of metastases, stage IV and staging T4. We were able to find relation between the expression of proteins NIS, p53 and MUC1 and prognostic of the studied patients

ASSUNTO(S)

mucinas antibody iodine cancer gene cancer evolution gene iodo mucin evolução anticorpos

ACESSO AO ARTIGO

Documentos Relacionados